$BCRX News
Last published 1w ago
- 1w agoBCRXBioCryst to Present at Upcoming Investor ConferencesGlobeNewswireRESEARCH TRIANGLE PARK, N.C., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: 2026 Jefferies Global
- 1w agoBCRXBIOCRYST PHARMACEUTICALS INC - PRESS RELEASEEarnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 1w agoBCRXBioCryst Reports Third Quarter 2026 Financial ResultsGlobeNewswire— Total net revenue of $180.3 million and ORLADEYO® net revenue of $174.8 million — — Operating profit of $53.3 million and Non-GAAP operating profit of $86.5 million — — Maintained Full Year 2026 ORLADEYO revenue
- 1w agoBCRXBioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific MeetingGlobeNewswire—New data highlight BioCryst's commitment to advancing a portfolio of therapies for people living with HAE— RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.
- 3w agoBCRXBioCryst to Report Third Quarter 2026 Financial Results on November 4GlobeNewswireRESEARCH TRIANGLE PARK, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2026 financial results on Wednesday,
- 3w agoBCRXBioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAEGlobeNewswire—Expands BioCryst portfolio of targeted oral prophylactic therapy options to meet patients’ individual needs and preferences— —ORLADEYO is the first and only targeted oral prophylactic therapy with options for HAE
- 3w agoBCRXApproval of Orladeyo, Nda #214094 (Labeling)FDA Approved DrugsApproval Date: 10/16/2026; Drug Name: Orladeyo, Nda #214094; Active Ingredients: BEROTRALSTAT DIHYDROCHLORIDE; Company: Biocryst; Submission Status: Approval; Submission Classification: Labeling; Application Number: 214094
- 2mo agoBCRXBioCryst to Present at Upcoming Investor ConferenceGlobeNewswireRESEARCH TRIANGLE PARK, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Morgan Stanley 24th Annual Global Healthcare
- 2mo agoBCRXBioCryst is profitable. Now it wants to buy more rare disease drugsCNBCRare disease drug development is getting a boost from new funding models and a growing group of smaller biotech buyers.
- 2mo agoBCRXBioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in JapanGlobeNewswire— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to <12 years in Japan — RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals,
- 3mo agoBCRXBioCryst Reports Second Quarter 2026 Financial ResultsGlobeNewswire— Total net revenue of $218.3 million and ORLADEYO® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 million — — Maintained Full Year 2026
- 3mo agoBCRXBioCryst to Report Second Quarter 2026 Financial Results on August 5GlobeNewswireRESEARCH TRIANGLE PARK, N.C., July 22, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2026 financial results on Wednesday, August
- 3mo agoBCRXBioCryst Appoints David W. Jenkins as Chief Scientific OfficerGlobeNewswireRESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ("BioCryst" or the "Company") today announced the appointment of David W. Jenkins, MA, PhD,
- 4mo agoBCRXBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireRESEARCH TRIANGLE PARK, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired
- 4mo agoBCRXBioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research FacilityGlobeNewswire—Advances strategic shift toward a disciplined research model prioritizing external innovation to accelerate rare disease pipeline growth— —Completes enrollment in Phase 3 ALPHA-ORBIT for navenibart, largest pivotal
- 5mo agoBCRXBioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual MeetingGlobeNewswire— Growing body of ORLADEYO® clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization across diverse patient populations — New post hoc analysis of
- 5mo agoBCRXBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireRESEARCH TRIANGLE PARK, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst's board of directors granted nine newly-hired
- 5mo agoBCRXBioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual MeetingGlobeNewswireRESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioedema (HAE) portfolio
- 6mo agoBCRXBioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026GlobeNewswireRESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new real-world evidence at the 2026 International Society for
- 6mo agoBCRXBioCryst Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire— Q1 2026 ORLADEYO® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) — — Announced licensing agreement for European commercial rights to navenibart for $70M
- 6mo agoBCRXBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireRESEARCH TRIANGLE PARK, N.C., May 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst's board of directors granted six newly-hired
- 6mo agoBCRXBioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary AngioedemaGlobeNewswire— BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibart for hereditary angioedema in Europe — — BioCryst to receive $70M upfront, up to $275M in future regulatory and sales
- 6mo agoBCRXBioCryst to Present at Upcoming Investor ConferencesGlobeNewswireRESEARCH TRIANGLE PARK, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: Bank of America Health
- 7mo agoBCRXBioCryst to Report First Quarter 2026 Financial Results on May 6GlobeNewswireRESEARCH TRIANGLE PARK, N.C. , April 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2026 financial results on Wednesday, May 6,
- 7mo agoBCRXBioCryst Appoints Sandeep M. Menon Chief Research and Development OfficerGlobeNewswire— Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval — RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst
- 7mo agoBCRXBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireRESEARCH TRIANGLE PARK, N.C., April 03, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst's board of directors granted 12 newly-hired
- 8mo agoBCRXBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireRESEARCH TRIANGLE PARK, N.C., March 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst's board of directors granted six newly-hired
- 8mo agoBCRXBioCryst Reports Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswire—Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A. on October 1,
- 8mo agoBCRXBioCryst to Present at Upcoming Investor ConferenceGlobeNewswireRESEARCH TRIANGLE PARK, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the T.D. Cowen 46th Annual Health Care Conference in
- 9mo agoBCRXBioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual MeetingGlobeNewswireRESEARCH TRIANGLE PARK, N.C., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present nine abstracts from its hereditary angioedema (HAE) portfolio
- 9mo agoBCRXBioCryst to Report Fourth Quarter 2025 Financial Results on February 26GlobeNewswireRESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2025 financial results on Thursday,
- 9mo agoBCRXBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireRESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst's board of directors granted 24 newly-hired
- 9mo agoBCRXBioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary AngioedemaGlobeNewswireRESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initially announced on
- 10mo agoBCRXBioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance RangeGlobeNewswire–Excluding European ORLADEYO revenue for the full year 2025, preliminary 2025 ORLADEYO net revenue was $563 million (+43 percent y-o-y on a comparable basis)– –ORLADEYO net revenue expected to be between $625 million
- 11mo agoBCRXBioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 YearsGlobeNewswire–ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older–-Oral pellet formulation provides child-friendly method of administration- –Showed early and sustained reductions in
- 11mo agoBCRXApproval of Orladeyo, Nda #219776 (Labeling)FDA Approved DrugsApproval Date: 12/11/2025; Drug Name: Orladeyo, Nda #219776; Active Ingredients: BEROTRALSTAT; Company: Biocryst Pharmaceuticals, Inc; Submission Status: Approval; Submission Classification: Labeling; Application Number: 219776
- 11mo agoBCRXBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireRESEARCH TRIANGLE PARK, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst's board of directors granted four newly-hired
- 11mo agoBCRXBioCryst Receives Early Termination of HSR Waiting Period for Astria AcquisitionGlobeNewswireRESEARCH TRIANGLE PARK, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it has received early termination of the waiting period under the Hart-Scott-Rodino
- 1y agoBCRXBioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)GlobeNewswire– Findings highlight negative psychosocial impact of HAE attacks and resulting ED/hospital visits on pediatric patients and their caregivers – – ORLADEYO oral granules demonstrated early and sustained reduction in
- 1y agoBCRXBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireRESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst's board of directors granted three newly-hired
- 1y agoBCRXBioCryst to Present at Upcoming Investor ConferenceGlobeNewswireRESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Jefferies Global Healthcare Conference in London on
- 1y agoBCRXBioCryst Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire—Q3 2025 ORLADEYO net revenue of $159.1 million (+37 percent y-o-y)— —Q3 2025 operating profit of $29.6 million (+285 percent y-o-y); non-GAAP operating profit of $51.7 million (+107 percent y-o-y); continued
- 1y agoBCRXBioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific MeetingGlobeNewswireRESEARCH TRIANGLE PARK, N.C., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts at the Annual Scientific Meeting of the
- 1y agoBCRXBioCryst to Report Third Quarter 2025 Financial Results on November 3GlobeNewswireRESEARCH TRIANGLE PARK, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2025 financial results on Monday, November 3,
- 1y agoATXSBCRXBioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth ProfileGlobeNewswire– Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio – – Solidifies double digit growth trajectory for HAE portfolio over the
- 1y agoATXSBCRXBioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth ProfileBusiness Wire– Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio – – Solidifies double digit growth trajectory for HAE portfolio over the
- 1y agoBCRXBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireRESEARCH TRIANGLE PARK, N.C., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst's board of directors granted eight newly-hired
- 1y agoBCRXBioCryst Completes Sale of European ORLADEYO® (berotralstat) BusinessGlobeNewswire– Transaction valued at $250 million, with up to $14 million in future milestones – – BioCryst will focus on driving ORLADEYO sales in the U.S. while Neopharmed Gentili will lead commercialization across Europe – –
- 1y agoBCRXBioCryst Pharmaceuticals, Inc. (BCRX) Presents at Cantor Global Healthcare Conference 2025 TranscriptEarnings Call Transcripts
- 1y agoBCRXBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireRESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst's board of directors granted nine newly-hired